Donate to Remove ads

Got a credit card? use our Credit Card & Finance Calculators

Thanks to eyeball08,Wondergirly,bofh,johnstevens77,Bhoddhisatva, for Donating to support the site

AstraZeneca Announcement

For discussion of the practicalities of setting up and operating income-portfolios which follow the HYP Group Guidelines. READ Guidelines before posting
Forum rules
Tight HYP discussions only please - OT please discuss in strategies
Post Reply Previous topicNext topic
idpickering
The full Lemon
Posts: 11339
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2472 times
Been thanked: 5791 times

AstraZeneca Announcement

#118297

Postby idpickering » February 15th, 2018, 7:11 am

Selumetinib in NF1 gets FDA orphan drug status

AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).


Full item here;

https://www.investegate.co.uk/astrazene ... 00059694E/
Top
Post Reply Previous topicNext topic

Return to “HYP Practical (See Group Guidelines)”

Who is online

Users browsing this forum: No registered users and 63 guests